XMP1 Stock Chart & Stats
€2.56
-€0.04(-1.07%)
At close: 4:00 PM EDT
€2.56
-€0.04(-1.07%)
Day’s Range― - ―
52-Week Range€1.55 - €28.15
Previous CloseN/A
Volume0.00
Average Volume (3M)72.00
Market Cap
€12.46M
Enterprise Value€21.60
Total Cash (Recent Filing)€8.59M
Total Debt (Recent Filing)€44.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Oct 15, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1033.41
Shares Outstanding7,589,774
10 Day Avg. Volume216
30 Day Avg. Volume72
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.15
Price to Sales (P/S)2.42
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€32.66Price Target Upside1175.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.15
Revenue Forecast (FY)€5.49M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsThe very high gross margin indicates that the core product can retain substantial economics after direct costs. If revenue scales, this margin structure could provide operating leverage and help fund commercialization, although current operating expenses still prevent the business from reaching profitability.
Improved Balance Sheet LeverageCurrent leverage is modest compared with the company’s prior periods, when debt was higher and equity was negative. This gives Cerenome a less burdened capital structure and reduces immediate debt pressure, supporting financial flexibility while it works to develop and commercialize its platform.
Extended Funding RunwayNew senior financing provides capital for working capital and commercial expansion of the CNSide assay platform, potentially allowing development and commercialization to continue over multiple quarters. A longer runway reduces near-term funding urgency, although secured terms, interest and royalty obligations remain important constraints.
Bears Say
Declining Small Revenue BaseA declining and small revenue base limits the company’s ability to absorb its fixed operating expenses and makes progress toward self-funded growth more difficult. Continued revenue contraction would also reduce the potential operating leverage implied by the high gross margin and increase reliance on external capital.
Deep Persistent LossesPersistent losses show that current revenue is far below the level needed to support research and operating spending. The deeply negative net margin and continuing losses indicate that breakeven remains distant, leaving future financial performance dependent on substantial scale or successful commercialization.
Sustained Cash BurnMaterially negative operating and free cash flow means the business is not currently funding itself through operations. Sustained cash consumption can require repeated financing, increasing exposure to secured borrowing, interest, royalties or dilution and limiting flexibility if commercialization takes longer than expected.
Cerenome News
XMP1 FAQ
What was Cerenome’s price range in the past 12 months?
Cerenome lowest stock price was €1.55 and its highest was €28.15 in the past 12 months.
What is Cerenome’s market cap?
Cerenome’s market cap is €12.46M.
When is Cerenome’s upcoming earnings report date?
Cerenome’s upcoming earnings report date is Oct 15, 2026 which is in 14 days.
How were Cerenome’s earnings last quarter?
Cerenome released its earnings results on Aug 14, 2026. The company reported -€1.156 earnings per share for the quarter, missing the consensus estimate of -€0.777 by -€0.38.
Is Cerenome overvalued?
According to Wall Street analysts Cerenome’s price is currently Undervalued.
Does Cerenome pay dividends?
Cerenome does not currently pay dividends.
What is Cerenome’s EPS estimate?
Cerenome’s EPS estimate is -0.92.
How many shares outstanding does Cerenome have?
Cerenome has 7,589,774 shares outstanding.
What happened to Cerenome’s price movement after its last earnings report?
Cerenome reported an EPS of -€1.156 in its last earnings report, missing expectations of -€0.777. Following the earnings report the stock price went down -5.145%.
Which hedge fund is a major shareholder of Cerenome?
Currently, no hedge funds are holding shares in DE:XMP1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cerenome
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
XMP1 Stock 12 Month Forecast
Average Price Target
€32.66
▲(1175.89% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―